PG
CLVS

PEAK6 Group’s Clovis Oncology, Inc. CLVS Stock Holding History

PEAK6 Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,833
Closed -$99K – 5210
2015
Q4 		$99K Buy
+2,833
New +$183K ﹤0.01% 3964
2014
Q2 		– Sell
-1,750
Closed -$121K – 5281
2014
Q1 		$121K Buy
+1,750
New +$129K ﹤0.01% 3794

Other funds holding CLVS

PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

PEAK6 Group's CLVS Position: Q1 2016 in Review

PEAK6 Group sold out of Clovis Oncology, Inc. (CLVS) in Q1 2016, closing a stake of 2,833 shares — an estimated $99K sold.

PEAK6 Group first reported a position in CLVS in Q1 2014 and held it in 2 quarters. The position peaked at $121K in Q1 2014. 135 funds tracked by Wall St. Rank hold CLVS as of Q1 2016.

  • PEAK6 Group reported no remaining Clovis Oncology, Inc. position as of Q1 2016 after selling out during the quarter.
  • PEAK6 Group sold 2,833 Clovis Oncology, Inc. shares in Q1 2016, an estimated $99K.
  • PEAK6 Group first reported a position in Clovis Oncology, Inc. in Q1 2014 and held it in 2 quarters.
  • PEAK6 Group's Clovis Oncology, Inc. position peaked at $121K in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2016.

Based on PEAK6 Group's 13F filing for Q1 2016, filed 13 May 2016.